SEC Form 4 · accession 0001209191-18-056704
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J. Scott Garland
Officer — President and CEO · Director
Period of report
Oct 31, 2018
Accepted (ET)
Oct 31, 2018 · 6:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 31, 2018 | A | 125,000 | $0.00 | A | 125,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $19.69 | Oct 31, 2018 | A | 250,000 | A | — | Oct 30, 2028 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest in equal annual installments on each of the first three anniversaries of the October 31, 2018 grant date, subject to Reporting Person's Continuous Service as of each such date.
- F2The Option vests as follows: 25% of the shares will vest one year from the Vesting Commencement Date of October 8, 2018, and the remaining shares shall vest ratably over the next 36 months.